Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
Group Sign-on Letter to Congress Opposing the Preserving Employee Wellness Programs Act (HR 1313)
-
ACMG Board Statement Regarding 2018 ACMG Annual Meeting to Be Held in Charlotte, NC and Discriminatory Legislation
-
ACMG Efforts Lead AMA Resolution 122 to Support Coverage of Medical Food Products
-
ACMG Comments to EEOC Concerning Proposed Rule Related to the Genetic Information Nondiscrimination Act (GINA)
-
ACMG Comments to OHRP Concerning Proposed Revisions to the Common Rule
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing